Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Non Operating Income (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Non Operating Income for 8 consecutive years, with -$304000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income rose 86.06% year-over-year to -$304000.0, compared with a TTM value of $8.8 million through Sep 2025, up 140.6%, and an annual FY2024 reading of -$739000.0, down 233.39% over the prior year.
  • Non Operating Income was -$304000.0 for Q3 2025 at X4 Pharmaceuticals, down from $528000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $24.9 million in Q3 2023 and bottomed at -$24.7 million in Q4 2023.
  • Average Non Operating Income over 5 years is $206789.5, with a median of -$635000.0 recorded in 2021.
  • Peak annual rise in Non Operating Income hit 9676.24% in 2024, while the deepest fall reached 11854.47% in 2024.
  • Year by year, Non Operating Income stood at -$1.1 million in 2021, then crashed by 226.98% to -$3.8 million in 2022, then crashed by 557.6% to -$24.7 million in 2023, then soared by 95.09% to -$1.2 million in 2024, then soared by 74.96% to -$304000.0 in 2025.
  • Business Quant data shows Non Operating Income for XFOR at -$304000.0 in Q3 2025, $528000.0 in Q2 2025, and $9.8 million in Q1 2025.